Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm.
Koos BoeveMirjam F MastikLorian Slagter-MenkemaBoukje A C van DijkJan L N RoodenburgBernard F A M van der LaanMax J H WitjesBert van der VegtEd SchuuringPublished in: Head & neck (2021)
Expression of cortactin is a promising immunohistochemical tumor marker to identify patients at low risk that may not benefit from SLNB or END.